Compare Iron Mountain Inc (IRM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Iron Mountain Inc trades at $111 (market cap $34.12B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Iron Mountain Inc is far larger — about 35.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Iron Mountain Inc pays a 3.02% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IRM | MRVI | |
|---|---|---|
Market Cap | $34.12B | $972.90M |
Volume | 1,143,756 | 4,325,710 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $9.00 |
52-Week Low | $78.86 | $2.83 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $53.53B | $1.08B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $110.86, down 3.68% on the day, amid a neutral technical signal. The company shows steady revenue growth, with 2025 revenue at $6.90B and a net income margin of 5.54%, though profitability has been volatile. Recent news highlights expansion in data centers and digital solutions, with a 300MW pipeline target. Analyst consensus is bullish with a $142.75 price target, but high debt levels and negative shareholder equity pose fundamental concerns.
The outlook for IRM is mixed; growth in digital and data center services offers upside, supported by strong analyst buy ratings. However, elevated valuation multiples, significant debt burden, and inconsistent earnings present risks. Investors should weigh the growth potential against financial leverage and margin pressures when considering a position.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
